Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Surfing the MASH Tsunami
S2-E9.3 — Introducing LIVErHEALTHY: a program for patients with Early Fatty Liver disease
Executives from Echosens, Chronwell and ModifyHealth join to introduce LIVErHEALTHY, their integrated program for early Fatty Liver disease that integrates non-invasive monitoring, technology-supported behavior support, nutritional counseling and delivery of medically-tailored meals.
This episode is sponsored by Echosens. to introduce LIVErHEALTHY. Echosens is partnering with Chronwell and ModifyHealth to offer LIVErHEALTHY, an integrated program of non-invasive monitoring, technology-supported behavior support, nutritional counseling and delivery of medically-tailored meals.
In this conversation, our sponsors introduce the LIVErHEALTHY program. First Dr. Juan Pablo Frías discusses why behavioral, lifestyle and diet interventions are so important in treating obesity and NASH patients. When Dr. Frías has finished, executives of the three LIVErHEALTHY partners each present the services they are offering through the program. Finally, Global Liver Institute President and CEO Donna Cryer and Dr. Mazen Nooureddin of Cedars Sinai in Los Angeles, CA join host Roger Green to ask several questions about the LIVErHEALTHY program. LIVErHEALTHY is an innovative, broad-spectrum approach that physicians can offer to obesity and NASH patients. You will want to learn about this program as something doctors can offer patients today as well as a platform for things to come.